sulfamethoxazole has been researched along with Malaria, Falciparum in 8 studies
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.
Malaria, Falciparum: Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
| Excerpt | Relevance | Reference |
|---|---|---|
| " falciparum is highly resistant to chloroquine and Fansidar, we conducted an in vivo study to evaluate the therapeutic response of proguanil plus sulfametoxazole against Plasmodium falciparum malaria." | 9.10 | Proguanil plus sulfamethoxazole in the treatment of uncomplicated Plasmodium falciparum malaria. ( Fontes, CJ; Pang, LW; Ribeiro, LC, 2002) |
| "Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis in HIV-uninfected, exposed (HUE) children variably reduces clinical malaria burden despite antifolate resistance, but data regarding achieved serum levels and adherence are lacking." | 7.88 | Sulfamethoxazole Levels in HIV-Exposed Uninfected Ugandan Children. ( Anok, A; Duffy, PE; Eastman, RT; Gabriel, EE; Hobbs, CV; Kasule, J; Neal, J; Newell, K; Penzak, S; Reynolds, SJ; Serwadda, D, 2018) |
| " falciparum is highly resistant to chloroquine and Fansidar, we conducted an in vivo study to evaluate the therapeutic response of proguanil plus sulfametoxazole against Plasmodium falciparum malaria." | 5.10 | Proguanil plus sulfamethoxazole in the treatment of uncomplicated Plasmodium falciparum malaria. ( Fontes, CJ; Pang, LW; Ribeiro, LC, 2002) |
| "Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis in HIV-uninfected, exposed (HUE) children variably reduces clinical malaria burden despite antifolate resistance, but data regarding achieved serum levels and adherence are lacking." | 3.88 | Sulfamethoxazole Levels in HIV-Exposed Uninfected Ugandan Children. ( Anok, A; Duffy, PE; Eastman, RT; Gabriel, EE; Hobbs, CV; Kasule, J; Neal, J; Newell, K; Penzak, S; Reynolds, SJ; Serwadda, D, 2018) |
| " When PS-15 was administered in combination with sulfamethoxazole to healthy Saimiri sciureus monkeys, the serum antimalarial activity was considerably greater than that observed in monkeys that received PS-15 alone." | 1.29 | The activity of PS-15 in combination with sulfamethoxazole. ( Rieckmann, KH; Yeo, AE, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasule, J | 1 |
| Gabriel, EE | 1 |
| Anok, A | 1 |
| Neal, J | 1 |
| Eastman, RT | 1 |
| Penzak, S | 1 |
| Newell, K | 1 |
| Serwadda, D | 1 |
| Duffy, PE | 1 |
| Reynolds, SJ | 1 |
| Hobbs, CV | 1 |
| Talawanich, Y | 1 |
| Kamchonwongpaisan, S | 1 |
| Sirawaraporn, W | 1 |
| Yuthavong, Y | 1 |
| Fontes, CJ | 1 |
| Ribeiro, LC | 1 |
| Pang, LW | 1 |
| Khalil, I | 1 |
| Rønn, AM | 1 |
| Alifrangis, M | 1 |
| Gabar, HA | 1 |
| Satti, GM | 1 |
| Bygbjerg, IC | 1 |
| Laufer, MK | 1 |
| Plowe, CV | 1 |
| Yeo, AE | 2 |
| Rieckmann, KH | 1 |
| Canfield, CJ | 1 |
| Milhous, WK | 1 |
| Ager, AL | 1 |
| Rossan, RN | 1 |
| Sweeney, TR | 1 |
| Lewis, NJ | 1 |
| Jacobus, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Trimethoprim-sulfamethoxazole Prophylaxis on Malaria Infection and Immunity in Children in Uganda[NCT02094508] | 173 participants (Actual) | Observational | 2014-03-07 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sulfamethoxazole and Malaria, Falciparum
| Article | Year |
|---|---|
Proguanil plus sulfamethoxazole in the treatment of uncomplicated Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Drug Administration Schedule; Drug Resistance; Drug | 2002 |
7 other studies available for sulfamethoxazole and Malaria, Falciparum
| Article | Year |
|---|---|
Sulfamethoxazole Levels in HIV-Exposed Uninfected Ugandan Children.
Topics: Anti-Retroviral Agents; Antimalarials; Drug Resistance; Female; Folic Acid Antagonists; HIV; HIV Inf | 2018 |
Use of bacterial surrogates as a tool to explore antimalarial drug interaction: Synergism between inhibitors of malarial dihydrofolate reductase and dihydropteroate synthase.
Topics: Antimalarials; Dapsone; Dihydropteroate Synthase; Drug Interactions; Drug Resistance; Drug Synergism | 2015 |
Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Dihydropteroate Synthase; Drug Resistance; G | 2003 |
Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?
Topics: HIV Infections; Humans; Malaria, Falciparum; Pyrimethamine; Sulfadoxine; Sulfamethoxazole; Trimethop | 2006 |
The activity of PS-15 in combination with sulfamethoxazole.
Topics: Animals; Antimalarials; Biological Assay; Drug Combinations; Drug Resistance, Multiple; Drug Synergi | 1994 |
PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists.
Topics: Administration, Oral; Animals; Antimalarials; Aotus trivirgatus; Atovaquone; Drug Synergism; Folic A | 1993 |
Direct comparison of antimalarial activity among PS-15 combination therapies by bioassay of serum samples from treated Saimiri sciureus.
Topics: Animals; Antimalarials; Atovaquone; Biological Assay; Dapsone; Disease Models, Animal; Drug Synergis | 1997 |